Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.91 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.65 |
| ▸ | FAP | Q12884 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Anhydrous SCHEMBL29355255 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL18894359 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL497725 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL39724 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL2040329 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL15531904 | 0.95 | CYP3A4 (0.82) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL18492311 | 0.94 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL3967109 | 0.94 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL22206868 | 0.94 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL22206865 | 0.94 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12099056-B2 | Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites | ORASURE TECHNOLOGIES, INC. (US) | 2024-09-24 | — | — | US | claimed |
| US-20240133877-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | ORASURE TECHNOLOGIES, INC. (US) | 2024-04-25 | — | — | US | claimed |
| EP-4262881-A2 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | OraSure Technologies, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| US-20220307066-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2022-09-29 | — | — | US | claimed |
| US-20220257619-A1 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE | DURECT CORPORATION | 2022-08-18 | — | — | US | claimed |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | ORASURE TECHNOLIGIES, INC. | 2022-06-23 | — | — | US | claimed |
| WO-2022133193-A2 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | ORASURE TECHNOLOGIES, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2021011891-A1 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. (US) | 2021-01-21 | — | — | WO | claimed |
| WO-2020252399-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2020-12-17 | — | — | WO | claimed |
| WO-2019021319-A1 | PHARMACEUTICAL COMPOSITIONS | CIPLA LIMITED (IN) | 2019-01-31 | — | — | WO | claimed |
| US-20260139294-A1 | DEVELOPMENT OF A RAPID ENZYMATIC ASSAY FOR ANTIRETROVIRAL DRUG MONITORING USING CRISPR REPORTERS | UNIVERSITY OF WASHINGTON (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | RES TRIANGLE INST (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4680243-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2006024668-A1 | HYDROCHLORIDE OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL] AMINO]BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024667-A1 | FURAMATE OF 4-( (4-( (4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL)AMINO)-2-PYRIMIDINYL)AMINO)BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1632232-A1 | Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006005720-A1 | COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005021001-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | CYP3A4 537/4885CYP2D6 1296/4885FAP 657/4885 |
| US-12099056-B2 | Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites | DNTT, SLC29A1, SAMHD1 | CYP3A4 143/4885CYP2D6 80/4885FAP 3277/4885 |
| US-20260139294-A1 | DEVELOPMENT OF A RAPID ENZYMATIC ASSAY FOR ANTIRETROVIRAL DRUG MONITORING USING CRISPR REPORTERS | APOBEC3A, RNGTT, APOBEC3B | CYP3A4 605/4885CYP2D6 965/4885FAP 1751/4885 |
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | CUTA, CD209, SLC19A1 | CYP3A4 3162/4885CYP2D6 2538/4885FAP 2732/4885 |
| US-20240133877-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | DNTT, DUT, SAMHD1 | CYP3A4 276/4885CYP2D6 117/4885FAP 3070/4885 |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | DNTT, SLC29A1, SAMHD1 | CYP3A4 143/4885CYP2D6 80/4885FAP 3277/4885 |
| US-20220257619-A1 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE | ADA, ADAR, TYMP | CYP3A4 229/4885CYP2D6 173/4885FAP 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.